Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival

OncoImmunology

Volumn 5, Issue 4, 2016, Pages

  Genßler, Sabrina ^a   Burger, Michael C ^b,c,d   Zhang, Congcong ^a,c,d   Oelsner, Sarah ^a   Mildenberger, Iris ^a,b   Wagner, Marlies ^b   Steinbach, Joachim P ^b,c   Wels, Winfried S ^a,c  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Partner Site   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cetuximab; chimeric antigen receptor; EGFR; EGFRvIII; glioblastoma; natural killer cells

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 84962787338     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1119354     Document Type: Article

References (43)

1. R.Stupp, W.P.Mason, M.J.van den Bent, M.Weller, B.Fisher, M.J.B.Taphoorn, K.Belanger, A.A.Brandes, C.Marosi, U.Bogdahn et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330
2. O.Bähr, U.Herrlinger, M.Weller, J.P.Steinbach. Very late relapses in glioblastoma long-term survivors. J Neurol 2009; 256:1756-8; PMID:19434438; http://dx.doi.org/10.1007/s00415-009-5167-6
3. S.H.Bigner, P.A.Humphrey, A.J.Wong, B.Vogelstein, J.Mark, H.S.Friedman, D.D.Bigner. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990; 50:8017-22; PMID:2253244
4. D.S.Salomon, R.Brandt, F.Ciardiello, N.Normanno. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232; PMID:7612182; http://dx.doi.org/10.1016/1040-8428(94)00144-I
5. B.Hasselbalch, U.Lassen, H.S.Poulsen, M.T.Stockhausen. Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling. Cancer Invest 2010; 28:775-87; PMID:20504227; http://dx.doi.org/10.3109/07357907.2010.483506
6. B.Thiessen, C.Stewart, M.Tsao, S.Kamel-Reid, P.Schaiquevich, W.Mason, J.Easaw, K.Belanger, P.Forsyth, L.McIntosh et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 2010; 65:353-61; PMID:19499221; http://dx.doi.org/10.1007/s00280-009-1041-6
7. T.E.Taylor, F.B.Furnari, W.K.Cavenee. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets 2012; 12:197-209; PMID:22268382; http://dx.doi.org/10.2174/156800912799277557
8. R.Nishikawa, X.D.Ji, R.C.Harmon, C.S.Lazar, G.N.Gill, W.K.Cavenee, H.J.Huang. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994; 91:7727-31; PMID:8052651; http://dx.doi.org/10.1073/pnas.91.16.7727
9. M.Nagane, A.Levitzki, A.Gazit, W.K.Cavenee, H.J.Huang. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 1998; 95:5724-9; PMID:9576951; http://dx.doi.org/10.1073/pnas.95.10.5724
10. J.H.Sampson, A.B.Heimberger, G.E.Archer, K.D.Aldape, A.H.Friedman, H.S.Friedman, M.R.Gilbert, J.E.Herndon2nd, R.E.McLendon, D.A.Mitchell et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:4722-9; PMID:20921459; http://dx.doi.org/10.1200/JCO.2010.28.6963
11. J.H.Sampson, B.D.Choi, L.Sanchez-Perez, C.M.Suryadevara, D.J.Snyder, C.T.Flores, R.J.Schmittling, S.K.Nair, E.A.Reap, P.K.Norberg et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 2014; 20:972-84; PMID:24352643; http://dx.doi.org/10.1158/1078-0432.CCR-13-0709
12. N.Müller, S.Michen, S.Tietze, K.Töpfer, A.Schulte, K.Lamszus, M.Schmitz, G.Schackert, I.Pastan, A.Temme. Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1alpha-secreting glioblastoma. J Immunother 2015; 38:197-210; PMID:25962108; http://dx.doi.org/10.1097/CJI.0000000000000082
13. T.Tonn, S.Becker, R.Esser, D.Schwabe, E.Seifried. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10:535-44; PMID:11522236; http://dx.doi.org/10.1089/15258160152509145
14. S.Arai, R.Meagher, M.Swearingen, H.Myint, E.Rich, J.Martinson, H.Klingemann. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10:625-32; PMID:18836917; http://dx.doi.org/10.1080/14653240802301872
15. T.Tonn, D.Schwabe, H.G.Klingemann, S.Becker, R.Esser, U.Koehl, M.Suttorp, E.Seifried, O.G.Ottmann, G.Bug. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 2013; 15:1563-70; PMID:24094496; http://dx.doi.org/10.1016/j.jcyt.2013.06.017
16. K.Schönfeld, C.Sahm, C.Zhang, S.Naundorf, C.Brendel, M.Odendahl, P.Nowakowska, H.Bönig, U.Köhl, S.Kloess et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther 2015; 23:330-8; PMID:25373520; http://dx.doi.org/10.1038/mt.2014.219
17. C.B.Jannot, R.R.Beerli, S.Mason, W.J.Gullick, N.E.Hynes. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 1996; 13:275-82; PMID:8710366
18. R.Beers, P.Chowdhury, D.Bigner, I.Pastan. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 2000; 6:2835-43; PMID:10914732
19. W.Wels, R.Beerli, P.Hellmann, M.Schmidt, B.M.Marte, E.S.Kornilova, A.Hekele, J.Mendelsohn, B.Groner, N.E.Hynes. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer 1995; 60:137-44; PMID:7814146; http://dx.doi.org/10.1002/ijc.2910600120
20. J.Lee, S.Kotliarova, Y.Kotliarov, A.Li, Q.Su, N.M.Donin, S.Pastorino, B.W.Purow, N.Christopher, W.Zhang et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9:391-403; PMID:16697959; http://dx.doi.org/10.1016/j.ccr.2006.03.030
21. J.P.Steinbach, A.Klumpp, H.Wolburg, M.Weller. Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Res 2004; 64:1575-8; PMID:14996711; http://dx.doi.org/10.1158/0008-5472.CAN-03-3775
22. A.Schulte, K.Liffers, A.Kathagen, S.Riethdorf, S.Zapf, A.Merlo, K.Kolbe, M.Westphal, K.Lamszus. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110delta. Neuro Oncol 2013; 15:1289-301; PMID:23877316; http://dx.doi.org/10.1093/neuonc/not093
23. S.Li, K.R.Schmitz, P.D.Jeffrey, J.J.Wiltzius, P.Kussie, K.M.Ferguson. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11; PMID:15837620; http://dx.doi.org/10.1016/j.ccr.2005.03.003
24. C.Hartmann, N.Müller, A.Blaukat, J.Koch, I.Benhar, W.S.Wels. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 2010; 29:4517-27; PMID:20514015; http://dx.doi.org/10.1038/onc.2010.195
25. M.C.Chamberlain. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011; 101:319-23; PMID:21052776; http://dx.doi.org/10.1007/s11060-010-0251-4
26. R.L.Hayes, M.Koslow, E.M.Hiesiger, K.B.Hymes, H.S.Hochster, E.J.Moore, D.M.Pierz, D.K.Chen, G.N.Budzilovich, J.Ransohoff. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995; 76:840-52; PMID:8625188; http://dx.doi.org/10.1002/1097-0142(19950901)76:5%3c840::AID-CNCR2820760519%3e3.0.CO;2-R
27. R.O.Dillman, C.M.Duma, P.M.Schiltz, C.DePriest, R.A.Ellis, K.Okamoto, L.D.Beutel, C.De Leon, S.Chico. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 2004; 27:398-404; PMID:15314549; http://dx.doi.org/10.1097/00002371-200409000-00009
28. F.B.Furnari, T.F.Cloughesy, W.K.Cavenee, P.S.Mischel. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer 2015; 15:302-10; PMID:25855404; http://dx.doi.org/10.1038/nrc3918
29. S.L.Maude, N.Frey, P.A.Shaw, R.Aplenc, D.M.Barrett, N.J.Bunin, A.Chew, V.E.Gonzalez, Z.Zheng, S.F.Lacey et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
30. J.Han, J.Chu, W.Keung Chan, J.Zhang, Y.Wang, J.B.Cohen, A.Victor, W.H.Meisen, S.H.Kim, P.Grandi et al. CAR-Engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep 2015; 5:11483; PMID:26155832; http://dx.doi.org/10.1038/srep11483
31. L.Frederick, X.Y.Wang, G.Eley, C.D.James. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60:1383-7; PMID:10728703
32. Q.W.Fan, C.K.Cheng, W.C.Gustafson, E.Charron, P.Zipper, R.A.Wong, J.Chen, J.Lau, C.Knobbe-Thomsen, M.Weller et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 2013; 24:438-49; PMID:24135280; http://dx.doi.org/10.1016/j.ccr.2013.09.004
33. M.Hegde, A.Corder, K.K.Chow, M.Mukherjee, A.Ashoori, Y.Kew, Y.J.Zhang, D.S.Baskin, F.A.Merchant, V.S.Brawley et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 2013; 21:2087-101; PMID:23939024; http://dx.doi.org/10.1038/mt.2013.185
34. Z.Grada, M.Hegde, T.Byrd, D.R.Shaffer, A.Ghazi, V.S.Brawley, A.Corder, K.Schönfeld, J.Koch, G.Dotti et al. TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids 2013; 2:e105; PMID:23839099; http://dx.doi.org/10.1038/mtna.2013.32
35. M.Schmidt, M.Maurer-Gebhard, B.Groner, G.Köhler, G.Brochmann-Santos, W.Wels. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors. Oncogene 1999; 18:1711-21; PMID:10208432; http://dx.doi.org/10.1038/sj.onc.1202489
36. L.A.Johnson, J.Scholler, T.Ohkuri, A.Kosaka, P.R.Patel, S.E.McGettigan, A.K.Nace, T.Dentchev, P.Thekkat, A.Loew et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 2015; 7:275ra22; PMID:25696001; http://dx.doi.org/10.1126/scitranslmed.aaa4963
37. H.Klingemann. Are natural killer cells superior CAR drivers? Oncoimmunology 2014; 3:e28147; PMID:25340009; http://dx.doi.org/10.4161/onci.28147
38. M.Maurer-Gebhard, M.Schmidt, M.Azemar, U.Altenschmidt, E.Stöcklin, W.Wels, B.Groner. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res 1998; 58:2661-6; PMID:9635594
39. N.Müller, C.Hartmann, S.Genssler, J.Koch, A.Kinner, M.Grez, W.S.Wels. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth. Int J Cancer 2014; 134:2547-59; PMID:24243620; http://dx.doi.org/10.1002/ijc.28585
40. C.Sahm, K.Schönfeld, W.S.Wels. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 2012; 61:1451-61; PMID:22310931; http://dx.doi.org/10.1007/s00262-012-1212-x
41. C.Demaison, K.Parsley, G.Brouns, M.Scherr, K.Battmer, C.Kinnon, M.Grez, A.J.Thrasher. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13:803-13; PMID:11975847; http://dx.doi.org/10.1089/10430340252898984
42. D.Hills, G.Rowlinson-Busza, W.J.Gullick. Specific targeting of a mutant, activated EGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer 1995; 63:537-43; PMID:7591264; http://dx.doi.org/10.1002/ijc.2910630414
43. P.Oberoi, R.A.Jabulowsky, H.Bähr-Mahmud, W.S.Wels. EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells. PLoS One 2013; 8:e61267; PMID:23573299; http://dx.doi.org/10.1371/journal.pone.0061267